VASO Restructures to Focus on Congestive Heart Failure
Vasomedical, Inc. (NASDAQ: VASO) announced an initiative to improve alignment of operations to pursue the congestive heart failure market. This initiative, which includes a workforce reduction plus tighter expense control, is expected to provide a clear focus on CHF investment and to reduce expenses by approximately $3 million over the next year.
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
